Morgan Stanley Bio Techne Corp Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Bio Techne Corp stock. As of the latest transaction made, Morgan Stanley holds 6,578,943 shares of TECH stock, worth $414 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

6,578,943

Previous 5,719,540 15.03%

Holding current value

$414 Million

Previous $335 Million 0.94%

% of portfolio

0.02%

Previous 0.02%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$46.66 - $58.38 $40.1 Million - $50.2 Million	859,403 Added 15.03%	6,578,943 $338 Million
Q1 2025 May 15, 2025	BUY	$58.47 - $78.75 $56.2 Million - $75.7 Million	961,015 Added 20.2%	5,719,540 $335 Million
Q4 2024 Feb 14, 2025	BUY	$66.37 - $78.17 $6.7 Million - $7.89 Million	100,934 Added 2.17%	4,758,525 $343 Million
Q3 2024 May 14, 2025	BUY	$70.96 - $82.35 $17.5 Million - $20.3 Million	246,895 Added 5.6%	4,657,591 $372 Million
Q3 2024 Nov 14, 2024	BUY	$70.96 - $82.35 $17.5 Million - $20.3 Million	246,895 Added 5.6%	4,657,591 $372 Million
Q2 2024 May 14, 2025	SELL	$62.12 - $84.15 $21.6 Million - $29.3 Million	-347,829 Reduced 7.31%	4,410,696 $316 Million
Q2 2024 Oct 17, 2024	BUY	$62.12 - $84.15 $13.7 Million - $18.5 Million	220,418 Added 5.26%	4,410,696 $316 Million
Q2 2024 Aug 14, 2024	BUY	$62.12 - $84.15 $13.7 Million - $18.5 Million	220,418 Added 5.26%	4,410,696 $316 Million
Q1 2024 Oct 17, 2024	SELL	$65.98 - $77.09 $14.5 Million - $17 Million	-220,418 Reduced 5.0%	4,190,278 $295 Million
Q1 2024 Aug 16, 2024	BUY	$65.98 - $77.09 $6.74 Million - $7.88 Million	102,183 Added 2.5%	4,190,278 $295 Million
Q1 2024 May 15, 2024	BUY	$65.98 - $77.09 $6.74 Million - $7.88 Million	102,183 Added 2.5%	4,190,278 $295 Million
Q4 2023 Aug 16, 2024	SELL	$52.83 - $78.22 $17 Million - $25.2 Million	-322,601 Reduced 7.31%	4,088,095 $315 Million
Q4 2023 Feb 13, 2024	BUY	$52.83 - $78.22 $41.3 Million - $61.2 Million	782,269 Added 23.66%	4,088,095 $315 Million
Q3 2023 Nov 15, 2023	BUY	$67.52 - $89.42 $9.7 Million - $12.9 Million	143,716 Added 4.54%	3,305,826 $225 Million
Q2 2023 Aug 14, 2023	SELL	$73.76 - $85.98 $1.63 Million - $1.9 Million	-22,072 Reduced 0.69%	3,162,110 $258 Million
Q1 2023 May 15, 2023	BUY	$71.62 - $86.62 $14.4 Million - $17.5 Million	201,552 Added 6.76%	3,184,182 $236 Million
Q4 2022 Feb 14, 2023	BUY	$80.67 - $352.29 $223 Million - $976 Million	2,769,642 Added 1300.37%	2,982,630 $247 Million
Q3 2022 Nov 14, 2022	SELL	$282.54 - $391.85 $4.98 Million - $6.9 Million	-17,616 Reduced 7.64%	212,988 $60.5 Million
Q2 2022 Oct 27, 2022	BUY	$322.67 - $449.65 $40.3 Million - $56.1 Million	124,828 Added 118.01%	230,604 $79.9 Million
Q2 2022 Aug 15, 2022	BUY	$322.67 - $449.65 $40.3 Million - $56.1 Million	124,828 Added 118.01%	230,604 $79.9 Million
Q1 2022 Oct 27, 2022	SELL	$353.85 - $487.79 $44.2 Million - $60.9 Million	-124,828 Reduced 54.13%	105,776 $45.8 Million
Q1 2022 May 13, 2022	BUY	$353.85 - $487.79 $3.75 Million - $5.18 Million	10,611 Added 11.15%	105,776 $45.8 Million
Q4 2021 Feb 14, 2022	SELL	$456.15 - $525.06 $9.26 Million - $10.7 Million	-20,306 Reduced 17.59%	95,165 $49.2 Million
Q3 2021 Nov 15, 2021	BUY	$444.87 - $538.88 $51.4 Million - $62.2 Million	115,471 New	115,471 $56 Million

Others Institutions Holding TECH

# of Institutions

614

Shares Held

161M

Call Options Held

225K

Put Options Held

80.8K

View Full List

About BIO-TECHNE Corp

Ticker TECH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,222,600
Market Cap $2.47B
Description
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures bi...

More about TECH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account